Topics

Pfizer reports positive phase 3 data in atopic dermatitis

05:15 EDT 7 Oct 2019 | Pharmafile

Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 inhibitor, abrocitinib, in patients aged 12 or over with moderate to severe atopic dermatitis.

The study, called JADE MONO-2, used 391 subjects and was designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over the course of 12 weeks.

read more

Original Article: Pfizer reports positive phase 3 data in atopic dermatitis

NEXT ARTICLE

More From BioPortfolio on "Pfizer reports positive phase 3 data in atopic dermatitis"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...